<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> 1 (GLP-1) receptor (GLP-1R) <z:chebi fb="4" ids="48705">agonists</z:chebi> and dipeptidyl peptidase-4 (DPP-4) inhibitors attenuate postprandial lipaemia through mechanisms that remain unclear </plain></SENT>
<SENT sid="1" pm="."><plain>As <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> is a contributing risk factor for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, we examined the mechanisms linking pharmacological and physiological regulation of GLP-1 action to control of postprandial <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Postprandial <z:chebi fb="23" ids="18059">lipid</z:chebi> synthesis and secretion were assessed in <z:mpath ids='MPATH_458'>normal</z:mpath> and <z:chebi fb="15" ids="28757">fructose</z:chebi>-fed hamsters and in <z:mp ids='MP_0002169'>wild-type</z:mp> mice that were treated with or without <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="39015">Apolipoprotein</z:chebi> B-48 (ApoB-48) synthesis and secretion were also examined in primary enterocyte cultures </plain></SENT>
<SENT sid="4" pm="."><plain>The importance of exogenous vs endogenous GLP-1R signalling for regulation of intestinal <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> synthesis and secretion was assessed in mice and hamsters treated with the GLP-1R <z:chebi fb="4" ids="48705">agonist</z:chebi> exendin-4, the GLP-1R <z:chebi fb="68" ids="48706">antagonist</z:chebi> exendin(9-39) and in Glp1r (+/+) vs Glp1r (-/-) mice </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:chebi fb="0" ids="40237">Sitagliptin</z:chebi> decreased fasting plasma triacylglycerol, predominantly in the <z:chebi fb="1" ids="39027">VLDL</z:chebi> fraction, as well as postprandial triacylglycerol-rich <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> (TRL)-triacylglycerol, TRL-cholesterol and TRL-ApoB-48 in hamsters and mice </plain></SENT>
<SENT sid="6" pm="."><plain>GLP-1R activation with exendin-4 alone also decreased plasma and TRL-ApoB-48 in hamsters and mice, and reduced secretion of ApoB-48 in hamster enterocyte cultures </plain></SENT>
<SENT sid="7" pm="."><plain>Conversely, blockade of endogenous GLP-1R signalling by the <z:chebi fb="68" ids="48706">antagonist</z:chebi> exendin(9-39) or genetic elimination of GLP-1R signalling in Glp1r (-/-) mice enhanced TRL-ApoB-48 secretion in vivo </plain></SENT>
<SENT sid="8" pm="."><plain>Co-administration of exendin(9-39) also abolished the hypolipidaemic effect of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS/INTERPRETATION: Potentiation of endogenous incretin action via DPP-4 inhibition or pharmacological augmentation of GLP-1R signalling reduces intestinal secretion of triacylglycerol, cholesterol and ApoB-48 </plain></SENT>
<SENT sid="10" pm="."><plain>Moreover, endogenous GLP-1R signalling is essential for the control of intestinal <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> biosynthesis and secretion </plain></SENT>
</text></document>